Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Alterity Therapeutics ( (AU:ATH) ) is now available.
Alterity Therapeutics has announced the expiry of 91,392,720 unexercised options (ASX code ATHAAD) with an exercise price of A$0.032, which lapsed on 6 January 2026. The cessation of these options removes a substantial block of potential dilution from the company’s capital structure, slightly simplifying its issued capital and clarifying the near‑term equity overhang for existing shareholders and prospective investors.
The most recent analyst rating on (AU:ATH) stock is a Buy with a A$0.01 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the AU:ATH Stock Forecast page.
More about Alterity Therapeutics
Alterity Therapeutics Limited is an Australian biotechnology company listed on the ASX under the code ATH, focused on developing therapeutic products, typically targeting neurodegenerative or related conditions. As a clinical‑stage life sciences firm, its activities centre on advancing drug candidates through research and development to address unmet medical needs in its chosen markets.
Average Trading Volume: 15,292,621
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$97.88M
See more insights into ATH stock on TipRanks’ Stock Analysis page.